About vTv Therapeutics Inc.
https://www.vtvtherapeutics.comvTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes.
CEO
Paul J. Sekhri
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-21 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:374.46K
Value:$14.98M
BLACKROCK FUND ADVISORS
Shares:245.2K
Value:$9.81M
PATHSTONE FAMILY OFFICE, LLC
Shares:242.94K
Value:$9.72M
Summary
Showing Top 3 of 36
About vTv Therapeutics Inc.
https://www.vtvtherapeutics.comvTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.7M ▲ | $-8.7M ▼ | 0% | $-1.08 ▼ | $-10.34M ▼ |
| Q2-2025 | $0 | $7.72M ▲ | $-6.05M ▼ | 0% | $-0.92 ▼ | $-7.72M ▼ |
| Q1-2025 | $0 ▼ | $6.5M ▲ | $-5.09M ▼ | 0% ▲ | $-0.77 ▼ | $-6.49M ▼ |
| Q4-2024 | $17K ▲ | $4.89M ▼ | $-3.63M ▲ | -21.38K% ▼ | $-0.63 ▲ | $-4.42M ▲ |
| Q3-2024 | $0 | $6.51M | $-4.78M | 0% | $-0.88 | $-5.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $98.5M ▲ | $99.49M ▲ | $28.95M ▲ | $70.54M ▲ |
| Q2-2025 | $25.92M ▼ | $26.45M ▼ | $24.04M ▲ | $2.76M ▼ |
| Q1-2025 | $31.06M ▼ | $32.03M ▼ | $23.13M ▼ | $7.92M ▼ |
| Q4-2024 | $36.75M ▼ | $38.27M ▼ | $23.96M ▼ | $12.2M ▼ |
| Q3-2024 | $41.57M | $43.16M | $25.25M | $15.01M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.7M ▼ | $-5.22M ▼ | $0 | $77.8M ▲ | $72.58M ▲ | $-5.22M ▼ |
| Q2-2025 | $-7.38M ▼ | $-5.09M ▲ | $0 | $-42K ▼ | $-5.14M ▲ | $-5.09M ▲ |
| Q1-2025 | $-6.22M ▼ | $-5.69M ▼ | $0 | $0 | $-5.69M ▼ | $-5.69M ▼ |
| Q4-2024 | $-3.63M ▲ | $-4.83M ▲ | $0 | $0 ▼ | $-4.83M ▼ | $-4.83M ▲ |
| Q3-2024 | $-5.84M | $-6.42M | $0 | $2.46M | $-3.96M | $-6.42M |
CEO
Paul J. Sekhri
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-21 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
SAMSARA BIOCAPITAL, LLC
Shares:374.46K
Value:$14.98M
BLACKROCK FUND ADVISORS
Shares:245.2K
Value:$9.81M
PATHSTONE FAMILY OFFICE, LLC
Shares:242.94K
Value:$9.72M
Summary
Showing Top 3 of 36